Ruiliyuan Biotechnology

Ruiliyuan Biotechnology (HRYZ Biotech) is a clinical-stage biotechnology company specializing in the discovery and development of T-cell receptor engineered T-cell (TCR-T) therapies and other advanced cell-based immunotherapies for solid tumors. Based in Shanghai and closely affiliated with the Hengrui Yuanzheng group, the company utilizes its proprietary ReGET platform to identify tumor-specific antigens and engineer high-affinity TCRs. Its lead clinical programs include HRYZ-T101, targeting HPV18 E7 for HPV-positive malignancies, and HRYZ-T102, targeting AFP for advanced hepatocellular carcinoma. The company also develops Multi-Antigen Stimulated Cell Therapy (MASCT) and TCR dual antibody products to provide comprehensive solutions for refractory cancers. Ruiliyuan has successfully advanced multiple candidates into clinical trials in China and continues to expand its pipeline through strategic academic and clinical collaborations.